Journal of the Peripheral Nervous System最新文献

{"title":"COQ7-Related Neuropathy: Two New Cases and Review of the Literature","authors":"Julian Theuriet,&nbsp;Shams Ribault,&nbsp;Fanny Fontaine,&nbsp;Naïg Gueguen,&nbsp;Arnaud Jacquier,&nbsp;Isabelle Quadrio,&nbsp;Zoe Dmitrievsky,&nbsp;Marina Konyukh,&nbsp;Dominique Bonneau,&nbsp;Stéphane Allouche,&nbsp;Julien Cassereau,&nbsp;Christophe Verny,&nbsp;Virginie Guillet-Pichon,&nbsp;Antoine Pegat","doi":"10.1111/jns.70132","DOIUrl":"10.1111/jns.70132","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Biallelic variants in <i>COQ7</i> have been associated with inherited neuropathy. <i>COQ7</i> encodes a mitochondrial protein directly involved in coenzyme Q10 (CoQ10) biosynthesis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Two unreported and unrelated cases of <i>COQ7</i>-related neuropathy are presented, along with a review of all previously published cases to highlight the key clinical features. The frequency of <i>COQ7</i> variants was assessed in our cohort of distal hereditary motor neuropathy (dHMN) patients with upper motor neuron (UMN) signs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The two patients were compound heterozygous for the <i>COQ7</i> variants c.197T&gt;A, p.(Ile66Asn) and c.478del, p.(Asp160Thrfs*11); the latter has not been reported. Symptoms began in childhood, and both were diagnosed with dHMN based on distal motor weakness predominantly affecting the lower limbs and a pure motor length-dependent axonal neuropathy on electrodiagnostic study. They had pes cavus and brisk reflexes. In the 28 patients identified in the literature, including the two reported herein, the median age at symptom onset was 10 years (IQR [5–11]). The predominant neuropathy subtype was dHMN (89%). Foot deformities were observed in 19/23 patients (83%). Signs of UMN involvement were present in 20/27 patients (74%). In fibroblasts, CoQ10 levels were low, and 6-demethoxy-CoQ10 (DMQ10) levels were elevated in all tested patients (8/8, 100%). No other case was identified in 71 patients with dHMN and UMN signs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p><i>COQ7</i>-related neuropathy is rare but should be considered in young patients presenting with distal hereditary motor neuropathy, especially when UMN signs are present. Elevated DMQ10 levels and low CoQ10 levels in fibroblasts represent valuable diagnostic biomarkers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 2","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jns.70132","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of Phrenic Nerve Conduction Study in the Electrodiagnosis of Guillain Barré Syndrome","authors":"Volkan Tasdemir,&nbsp;Nermin Gorkem Sirin,&nbsp;Sezin Alpaydın Baslo,&nbsp;Dilek Atakli,&nbsp;Aysun Soysal,&nbsp;Arman Cakar,&nbsp;Hacer Durmus Tekce,&nbsp;Yesim Parman,&nbsp;Mehmet Baris Baslo,&nbsp;Ali Emre Oge,&nbsp;Elif Kocasoy Orhan","doi":"10.1111/jns.70131","DOIUrl":"10.1111/jns.70131","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>To determine the role of phrenic nerve conduction studies (NCS) in identifying subtypes of Guillain-Barré syndrome (GBS) and to investigate the correlations between phrenic NCS and clinical and respiratory scores.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A clinical evaluation was conducted on 23 patients diagnosed with GBS, encompassing the Medical Research Council (MRC) sum scores, GBS disability scores, and Erasmus GBS Respiratory Insufficiency Scores (EGRIS). Electrodiagnostic studies (EDX) were conducted twice and bilateral phrenic NCSs once within the 6 weeks after symptom onset. The latency, peak-to-peak amplitude, and negative peak area of phrenic compound muscle action potential (CMAP) elicited using surface electrodes were measured, and the values indicating prolonged latency (≥ 110%–130% of upper limit of normal (ULN)) and/or prolonged negative peak duration (≥ 130% of ULN) were considered as demyelinating.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Phrenic NCSs revealed 87.0% sensitivity and 89.5% specificity in the diagnosis of demyelinating subtype (cut-off value of latency 8.6 ms). Most of the phrenic CMAP parameters revealed moderate correlations with clinical scores and with the results of median and ulnar EDX studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>Besides its importance for having correlations with clinical and respiratory features, phrenic NCS may improve the diagnostic sensitivity in differentiating GBS subtypes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 2","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jns.70131","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Equality and Socioeconomic Impact of Hereditary Sensory Neuropathy Type 1 (HSN1) in the UK","authors":"Caroline Kramarz,&nbsp;Lodina Recica,&nbsp;Jasper Morrow,&nbsp;Mariola Skorupinska,&nbsp;Alexander M. Rossor,&nbsp;Matilde Laurá,&nbsp;Mary M. Reilly","doi":"10.1111/jns.70133","DOIUrl":"10.1111/jns.70133","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Hereditary Sensory Neuropathy Type 1 (HSN1) is a rare autosomal dominant neuropathy caused by variants in the <i>SPTLC1</i> and <i>SPTLC2</i> genes, resulting in sensory loss, motor weakness, chronic ulceration, and risk of limb amputation. Whilst the clinical manifestations are well characterised, the socioeconomic and psychosocial impact remains under-researched and poorly understood. This pilot study aimed to assess the health equality and socioeconomic impact of HSN1 on affected individuals in the UK.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A novel 28-item anonymised questionnaire focusing on employment, healthcare access, finance, mobility, and wellbeing was distributed to 50 genetically confirmed HSN1 patients from an UK cohort. Responses were collected electronically. Quantitative and qualitative data were analysed descriptively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 37 participants (74%) responded. Of these, only 24% were in full-time work, with 24% taking early medical retirement. Nearly half (46%) felt the disease negatively impacted career progression. Although 49% requested workplace adjustments, responses were mixed, with some reporting inadequate or denied support. Healthcare access was inconsistent due to long wait times, restrictive referral criteria, and poor awareness of HSN1 outside specialist centres. Financial strain was common; 41% reported income loss, and 21% spent over £1000 annually on disease-related costs. Driving ability was affected in 48%, and over half reported reduced participation in social activities. Nearly half believed healthcare professionals lacked sufficient understanding of the disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>HSN1 imposes a substantial burden beyond physical symptoms, affecting employment, finances, independence, and mental health. These results highlight the need for better patient-centred care and improved education for non-specialist healthcare professionals. This is particularly timely in the context of emerging disease-modifying therapies such as L-serine and future gene therapy trials.</p>\u0000 \u0000 <p><b>Trial Registration:</b> SENSE trial NCT06113055.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 2","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Diabetic Peripheral Neuropathy: Can It Be Reversed? Arguments for and Against From a NEUROdiab Debate.","authors":"Gordon Sloan, Shazli Azmi, Stephanie Eid, Maryam Ferdousi, Johan Røikjer, Zoltan Kender, Luca D'Onofrio, Eleni Karlafti, Brian Callaghan, Bruce A Perkins","doi":"10.1111/jns.70124","DOIUrl":"10.1111/jns.70124","url":null,"abstract":"<p><p>Diabetic peripheral neuropathy (DPN) is a prevalent and disabling complication of diabetes, yet whether established clinical DPN is reversible remains debated. At the 35th Annual Meeting of NEUROdiab, a formal debate examined arguments 'for' and 'against' the proposition that clinical DPN can be reversed. This review summarises both perspectives and considers their implications for clinical practice and future research. Evidence supporting the reversibility of clinical DPN draws on four main observations. Therapies for hereditary transthyretin amyloidosis demonstrate that substantial improvement in a progressive length-dependent neuropathy is biologically achievable, providing a proof-of-concept in a different disease. Pancreatic transplantation in Type 1 diabetes leads to measurable improvements in large- and small-fibre indices. Structured lifestyle interventions and bariatric surgery improve intraepidermal nerve fibre density, suggesting that metabolic correction can promote neural repair. Finally, emerging agents such as topical oxybutynin show early promise in improving surrogate outcomes, reinforcing the argument that clinical DPN may be partially reversible. Arguments opposing reversibility emphasise that DPN resembles other microvascular complications, in which early abnormalities may regress but established clinical disease is not reversed. Heterogeneity in diagnostic thresholds, phenotype variability and inconsistent outcome measures complicates defining what constitutes true reversal. Long-term studies and major trials, including DCCT/EDIC and BARI 2D, demonstrate slowing of progression rather than restoration of normal nerve function. Moreover, numerous mechanistically promising agents have failed in human trials despite strong pre-clinical results. Collectively, these limitations support the view that established clinical neuropathy remains largely irreversible to date. Overall, the debate underscores that reversibility depends on timing, definitions and outcome thresholds. While early-stage dysfunction is more likely to be modifiable, complete restoration of established clinical DPN (such as full restoration of protective sensation) remains unproven. Future research should prioritise developing validated biomarkers and standardised endpoints in addition to searching for new therapeutics.</p>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 2","pages":"e70124"},"PeriodicalIF":3.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13181159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147963863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restless Legs Syndrome in Patients With PMP22-Related Neuropathies.","authors":"Bogdan Bjelica, Milorad Vujnic, Milica Vukojevic, Ivo Bozovic, Nikola Andrejic, Ivana Basta, Vidosava Rakocevic-Stojanovic, Stojan Peric","doi":"10.1111/jns.70123","DOIUrl":"10.1111/jns.70123","url":null,"abstract":"<p><strong>Background and aims: </strong>Restless legs syndrome (RLS) is frequently reported in peripheral neuropathies, but its prevalence and clinical correlates in Charcot-Marie-Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP) remain poorly defined. We aimed to determine RLS prevalence in CMT1A and HNPP and to assess associations with disease severity, muscle strength, disability, and quality of life (QoL).</p><p><strong>Methods: </strong>Forty-seven CMT1A and 18 HNPP patients were included. RLS was diagnosed according to the International Restless Legs Syndrome Study Group criteria, and RLS severity was assessed with the International Restless Legs Syndrome Severity Scale (IRLS-SS). MRC Sum Score (MRC-SS), Charcot-Marie-Tooth Examination Score (CMTES), Overall Neuropathy Limitations Scale (ONLS), Beck Depression Inventory (BDI), Fatigue Severity Scale (FSS), and the 36-Item Short Form Health Survey (SF-36) were recorded.</p><p><strong>Results: </strong>RLS was present in 29.8% of CMT1A and 38.9% of HNPP patients. CMT1A patients with RLS had longer disease duration (p = 0.05), worse muscle strength (p = 0.014), higher disease severity (p = 0.014), higher upper-limb (p = 0.005) and overall disability (p = 0.011), and higher fatigue severity (p = 0.011) compared with those without RLS. HNPP patients with RLS showed higher upper-limb (p = 0.034) and overall disability (p = 0.032), higher depression (p = 0.005), and fatigue severity (p = 0.018) than those without RLS. QoL was significantly impaired in patients with RLS in both groups, and RLS severity negatively correlated with physical and mental QoL domains.</p><p><strong>Interpretation: </strong>RLS is common in CMT1A and HNPP and is associated with increased disease severity, greater functional disability, and reduced QoL. Clinicians should screen for RLS in PMP22-related neuropathies and consider symptomatic management.</p>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 2","pages":"e70123"},"PeriodicalIF":3.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13126250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measurement of Red Blood Cell Sorbitol Dehydrogenase Activity for Fast Screening of SORD-Related Neuropathies.","authors":"Nicholas Moro, Stanislas Francois, Christel Grondin, Sirine Ben Salem, Sreekanth Rajagopal, Duru Aykut, Louisa Arezki, José Manuel Larramendi, Claire Berquet, Marjolaine Willems, Céline Bouchet-Séraphin, Lucas W Gauthier, Marina Konyukh, Juliette Svahn, Stéphane Moutereau, Katell Peoc'h, Céline Tard, Gorka Fernández-Eulate, Tanya Stojkovic, Arnaud Bruneel, Alexandre Raynor","doi":"10.1111/jns.70122","DOIUrl":"10.1111/jns.70122","url":null,"abstract":"<p><strong>Background and aims: </strong>To develop an assay to measure red blood cell (RBC) sorbitol dehydrogenase (SORD) activity for fast laboratory screening of SORD-related neuropathies, and to provide additional phenotypic arguments in case of ambiguous genetic results.</p><p><strong>Methods: </strong>Hemolysates were incubated in the presence of fructose and NADH to produce sorbitol and NAD⁺. The decrease in absorbance at λ = 340 nm was monitored throughout the course of the reaction. Results were expressed as % activity compared to a within-run control. A cohort of 38 individuals was evaluated over 13 runs: 13 individuals served as within-run controls, 3 were diagnosed with SORD deficiency, 2 were highly suspected of having SORD deficiency, 1 exhibited incidental genomic findings in the SORD gene, and 19 presented with neuropathy or myopathy of undetermined etiology.</p><p><strong>Results: </strong>RBC SORD activity was significantly reduced in individuals diagnosed with SORD deficiency when compared to within-run controls, whereas in contrast, individuals without SORD deficiency did not exhibit this reduction. A comparison of these two groups showed that activities were significantly lower in deficient individuals (p = 0.00006). A test cutoff of < 30% yielded 100% sensitivity and specificity to detect deficient individuals.</p><p><strong>Interpretation: </strong>This test provides a useful alternative to measuring plasma or urine sorbitol with mass spectrometry, allowing clinicians to directly evaluate SORD activity in RBC. As a result, it enables quick and convenient screening for SORD-related neuropathies during standard clinical procedures.</p>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 2","pages":"e70122"},"PeriodicalIF":3.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between Diabetes Distress, Diabetic Peripheral Neuropathy and Neuropathic Pain in People With Type 2 Diabetes-The Maastricht Study.","authors":"Alice Cardon, Bryan Cleal, Mette Due-Christensen, Nicole Dukers-Muijrers, Klaus Kirketerp-Møller, Anne Rasmussen, Tarunveer S Ahluwalia, Christian Stevns Hansen, Miranda T Schram, Annemarie Koster","doi":"10.1111/jns.70130","DOIUrl":"10.1111/jns.70130","url":null,"abstract":"<p><strong>Background and aims: </strong>Diabetic peripheral neuropathy (DPN) and neuropathic pain are associated with various psychosocial factors, but the effect of diabetes distress remains underexplored. This study examines the associations between diabetes distress, DPN, and neuropathic pain.</p><p><strong>Methods: </strong>A cross-sectional analysis on participants with type 2 diabetes from The Maastricht Study was conducted. Diabetes distress was assessed with the PAID-20 questionnaire and categorized as low (score < 16), moderate (score 17-39), and high (score ≥ 40). Neuropathic pain was measured with the DN4 questionnaire, while DPN was clinically assessed through vibration perception threshold. Logistic regression analyses on the outcomes DPN only, neuropathic pain, and both DPN and pain were conducted, adjusted for sociodemographic (age, sex, education) and clinical characteristics (insulin use, HbA1c, depression).</p><p><strong>Results: </strong>1418 participants were included (median age: 64 years, 68.4% male). Moderate and high diabetes distress were observed in 22.5% and 4.8% of participants. Moderate (adjusted OR: 1.95; 95% CI: 1.37-2.75) and high distress (adjusted OR: 3.64; 95% CI: 1.97-6.63) were associated with the presence of neuropathic pain, but not with DPN alone.</p><p><strong>Interpretation: </strong>Diabetes distress is strongly associated with neuropathic pain but not with DPN. These findings suggest that individuals with neuropathic pain may benefit from psychosocial screening and support.</p>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 2","pages":"e70130"},"PeriodicalIF":3.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Role of the Perineurium: Evidence for an Essential Function for Macrophage Maintenance and Increase in Isolated Peripheral Nerves.","authors":"Miriam Geldermann, Dennis Klein, Eva Maria Weiß, Rudolf Martini","doi":"10.1111/jns.70126","DOIUrl":"10.1111/jns.70126","url":null,"abstract":"<p><strong>Background and aims: </strong>It is an established view that the perineurium surrounding peripheral nerves fulfills pivotal barrier functions to protect nerve fibers from noxious agents of the nerve environment. Here we want to investigate whether the perineurium also influences other endoneurial cells, like macrophages.</p><p><strong>Methods: </strong>Peripheral nerve segments-either intact or deprived of their perineurium-were investigated in vitro for up to 9 days. Macrophages were quantified by immunohistochemistry using the pan-marker F4/80. Because elevated macrophage numbers can affect their proliferation and activation, we reduced their abundance in selected experiments by pretreating nerve donor mice with the CSF1-receptor inhibitor PLX5622.</p><p><strong>Results: </strong>Endoneurial macrophage numbers in isolated nerve segments increased throughout the entire observation period. Removal of the perineurium caused a rapid and robust decline of macrophage numbers, reflecting its role on macrophage maintenance and expansion. Under these conditions, Schwann cells adopted an autophagic phenotype. When macrophages were pharmacologically reduced in number, they still preserved their capacity to expand in the normal nerve segments, with an initial preferential accumulation within the peripheral nerve region near the perineurium. Removal of the perineurium prior to culturing nerves with reduced macrophage numbers resulted again in a substantial loss of macrophages.</p><p><strong>Interpretation: </strong>We identified a pivotal role of the perineurium in supporting macrophage maintenance and expansion. The perineurium may serve as a source of trophic factors and/or may form a barrier maintaining a critical concentration of trophic factors within the endoneurium. Additionally, macrophages may originate from a cell pool within the perineurium.</p>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 2","pages":"e70126"},"PeriodicalIF":3.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147982181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 2","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148085379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 2","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148088004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}